Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Aidan Fry
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
Teva is eligible for compensation due to having been kept off the Canadian bortezomib market by Janssen suing for infringement of two patents that were subsequently found to be obvious.
Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.
Gilead’s Truvada is not entitled to an SPC in the Netherlands because the patent on which the SPC application referred mentions only one of the two active ingredients in the combination antiretroviral.
Amid market shortages of the pediatric cancer treatment as Pfizer struggles to meet demand, Teva has decided to resume producing vincristine in the US and plans to start shipments next year.
Apotex has failed to convince a Canadian federal court that a patent protecting Janssen’s Zytiga abiraterone brand until August 2027 is invalid and not infringed by its proposed generic version of the prostate-cancer treatment.